In the phase 2 FASCINATION trial, researchers sought to improve the rate of major molecular response 4 in patients newly diagnosed with CML.

Chronic myeloid leukemia highlights from ASH 2025 include data on nilotinib vs imatinib, asciminib in second line, somatic ...

Investing.com -- Enliven Therapeutics (NASDAQ:ELVN) stock surged 7% Thursday after the biopharmaceutical company reported ...

A total of 610 (30%) patients had ACAs in addition to t(9;22)(q34;q11.2)/BCR-ABL. Of note, cases with chromosomal changes in Ph-negative cells were not considered as ACAs. Of 610 cases with ACAs, 183 ...

Imatinib, a selective inhibitor of the BCR-ABL tyrosine kinase, produces high response rates in patients with chronic-phase chronic myeloid leukemia (CML) who have had no response to interferon alfa.